PBE ETF: A Comprehensive Guide to Its Fundamentals and Performance
ByAinvest
Tuesday, Jul 22, 2025 7:33 am ET1min read
ALNY--
PBE is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The fund's heaviest allocation is in the Healthcare sector, with approximately 99.8% of the portfolio. Among its top holdings, Illumina Inc (ILMN) accounts for about 5.81% of total assets, followed by Alnylam Pharmaceuticals Inc (ALNY) and Royalty Pharma Plc (RPRX) [1].
The fund has experienced a challenging year, with a loss of about -3.56% so far in 2025 and a decline of -6.19% over the past year (as of July 22, 2025). During this period, PBE has traded between $56.01 and $72.24. The ETF has a beta of 0.76 and a standard deviation of 21.29% for the trailing three-year period, indicating a higher risk profile compared to peers [1].
Investors seeking to outperform the Health Care ETFs segment may find PBE to be a reasonable option. However, alternatives such as the SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB) are also available. XBI tracks the S&P Biotechnology Select Industry Index and has $4.65 billion in assets, while IBB tracks the Nasdaq Biotechnology Index and has $5.28 billion in assets. Both alternatives have lower expense ratios, at 0.35% and 0.45%, respectively [1].
In conclusion, the Invesco Biotechnology & Genome ETF (PBE) offers broad exposure to the Health Care ETFs category through a smart beta strategy. While the fund has experienced recent performance challenges, it remains a viable option for investors seeking to outperform the segment. For more information, please visit the Zacks ETF Center.
References:
[1] https://finviz.com/news/110257/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now
IBB--
ILMN--
IVZ--
PBE--
The Invesco Biotechnology & Genome ETF (PBE) is a smart beta ETF launched in 2005, offering broad exposure to the Health Care ETFs category. The fund tracks the Dynamic Biotechnology & Genome Intellidex Index, seeking to match the performance of the index. With $222.64 million in assets, PBE has an expense ratio of 0.58% and a 12-month trailing dividend yield of 0.26%. The fund's heaviest allocation is in the Healthcare sector, with holdings including Illumina Inc (ILMN), Alnylam Pharmaceuticals Inc (ALNY), and Royalty Pharma Plc (RPRX).
The Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange-traded fund (ETF) launched on June 23, 2005, offering broad exposure to the Health Care ETFs category. The fund, managed by Invesco, aims to match the performance of the Dynamic Biotechnology & Genome Intellidex Index. With $222.64 million in assets under management, PBE has an expense ratio of 0.58% and a 12-month trailing dividend yield of 0.26% [1].PBE is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The fund's heaviest allocation is in the Healthcare sector, with approximately 99.8% of the portfolio. Among its top holdings, Illumina Inc (ILMN) accounts for about 5.81% of total assets, followed by Alnylam Pharmaceuticals Inc (ALNY) and Royalty Pharma Plc (RPRX) [1].
The fund has experienced a challenging year, with a loss of about -3.56% so far in 2025 and a decline of -6.19% over the past year (as of July 22, 2025). During this period, PBE has traded between $56.01 and $72.24. The ETF has a beta of 0.76 and a standard deviation of 21.29% for the trailing three-year period, indicating a higher risk profile compared to peers [1].
Investors seeking to outperform the Health Care ETFs segment may find PBE to be a reasonable option. However, alternatives such as the SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB) are also available. XBI tracks the S&P Biotechnology Select Industry Index and has $4.65 billion in assets, while IBB tracks the Nasdaq Biotechnology Index and has $5.28 billion in assets. Both alternatives have lower expense ratios, at 0.35% and 0.45%, respectively [1].
In conclusion, the Invesco Biotechnology & Genome ETF (PBE) offers broad exposure to the Health Care ETFs category through a smart beta strategy. While the fund has experienced recent performance challenges, it remains a viable option for investors seeking to outperform the segment. For more information, please visit the Zacks ETF Center.
References:
[1] https://finviz.com/news/110257/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet